BIOSYNTH
9.5.2023 11:01:34 CEST | Business Wire | Press release
Biosynth, a supplier of critical raw materials to the life science industry, announces today that it has acquired Cambridge Research Biochemicals (“CRB”), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.
CRB brings a wealth of expertise to Biosynth’s peptide division, which has existing operations in the US and the Netherlands. This includes leading expertise in complex peptide chemistry and fluorescent dye labelling. CRB also brings additional custom antibody capacity in Europe, to support customers through the generation of novel, complex or unusual mono- and poly-clonal antibodies unavailable in catalogs.
Dr. Urs Spitz, CEO and President of Biosynth, said, “CRB has a long history in the peptide and antibody field, and we are excited to welcome their highly skilled team to our growing peptide division. Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high quality antibodies.”
“We are excited to be joining the Biosynth family”, added Emily Humphrys, Managing Director of Cambridge Research Biochemicals. “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.”
--ends--
About Biosynth
Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.
About Cambridge Research Biochemicals
Cambridge Research Biochemicals (www.crbdiscovery.com) is a leading independent producer of custom-made peptide and antibody tools, supplying researchers in the pharmaceutical, life science and academic sectors worldwide. The primary applications of its products are as custom-made, laboratory scale reagents for proof of principal studies within early phase drug discovery and to support biomarker programmes in clinical studies. The company produces all flavours of peptides from simple to modified, stable and radio-labelled to dye labelled from milligrams to gram-scale to the highest levels of purity. In addition, CRB is a recognised expert at generating highly specific and targeted antibodies (both polyclonal and monoclonal). Fluorescent dye labelling is also a focus.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005621/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 08:30:00 CEST | Press release
Reorganization of Plenitude’s capital structure expands Ares’ economic and governance participation in the company Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that suppo
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 08:10:00 CEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
Thales Launches Sentinel Envelope Plus to Protect Software Against AI-Assisted Reverse Engineering1.10.2026 08:01:00 CEST | Press release
Sentinel Envelope Plus, a new advanced software protection add-on, helps software vendors protect compiled applications against AI-assisted reverse engineering, automated vulnerability discovery, and exploit generation without requiring source code changes In a controlled test, an AI agent identified eight of 10 vulnerabilities in an unprotected application; once the application was protected with Sentinel Envelope Plus, it found none, and the analysis was halted after nearly seven hours. Thales, a global leader in advanced technologies, today announced Sentinel Envelope Plus, a new addition to its Sentinel Envelope software protection solution that significantly hardens compiled applications against AI-assisted reverse engineering, automated zero-day vulnerability discovery, and automated exploit generation. Sentinel Envelope Plus applies multiple layers of protection to software applications, without requiring source code changes or any special compilation environments. This press re
NHOA Energy Achieves UNI/PdR 125:2022 Gender Equality Certification1.10.2026 08:00:00 CEST | Press release
The certification marks another step in NHOA Energy’s commitment to equal opportunities and inclusive workplace NHOA Energy, global provider of utility-scale energy storage systems, has obtained the UNI/PdR 125:2022 Gender Equality Certification for its Gender Equality Management System in Italy. Issued by RINA following an independent audit, the certification evaluates the Company’s approach to gender equality through qualitative and quantitative indicators across six key areas: recruitment and hiring, career management, pay equity, parenting and caregiving, work-life balance, and the prevention of workplace abuse and harassment. “Building a strong company also means creating an environment where people have equal opportunities to contribute, grow and lead. This certification is an important recognition of the work already done, but above all a commitment to continue improving the way we support our People and strengthen our culture,” said Anita Maria Ganassali, VP Human Capital of NH
Thales Strengthens Data Security Posture Management to Address Emerging Risks of AI1.10.2026 08:00:00 CEST | Press release
Thales’ CipherTrust Data Security Posture Management platform brings together data discovery, risk analysis and integrated protection to help organizations move from identifying exposure to actively reducing data risk. It helps enterprises protect sensitive data as AI applications and autonomous agents gain access to information across increasingly complex environments. It connects prioritized data risks with protection capabilities across all environments; cloud, on-premises and hybrid environments. Thales, a global leader in advanced technologies for cybersecurity markets, today announced CipherTrust Data Security Posture Management (DSPM). It is the first purpose-built DSPM offering designed to help organizations go beyond discovering exposed sensitive data and applying access-based remediation, enabling them to prioritize risks and protect their most sensitive data directly through encryption, masking, or tokenization natively within the platform. This press release features multim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom